Back to Search Start Over

KRAS signaling in malignant pleural mesothelioma.

Authors :
Marazioti A
Krontira AC
Behrend SJ
Giotopoulou GA
Ntaliarda G
Blanquart C
Bayram H
Iliopoulou M
Vreka M
Trassl L
Pepe MAA
Hackl CM
Klotz LV
Weiss SAI
Koch I
Lindner M
Hatz RA
Behr J
Wagner DE
Papadaki H
Antimisiaris SG
Jean D
Deshayes S
Grégoire M
Kayalar Ö
Mortazavi D
Dilege Ş
Tanju S
Erus S
Yavuz Ö
Bulutay P
Fırat P
Psallidas I
Spella M
Giopanou I
Lilis I
Lamort AS
Stathopoulos GT
Source :
EMBO molecular medicine [EMBO Mol Med] 2022 Feb 07; Vol. 14 (2), pp. e13631. Date of Electronic Publication: 2021 Dec 13.
Publication Year :
2022

Abstract

Malignant pleural mesothelioma (MPM) arises from mesothelial cells lining the pleural cavity of asbestos-exposed individuals and rapidly leads to death. MPM harbors loss-of-function mutations in BAP1, NF2, CDKN2A, and TP53, but isolated deletion of these genes alone in mice does not cause MPM and mouse models of the disease are sparse. Here, we show that a proportion of human MPM harbor point mutations, copy number alterations, and overexpression of KRAS with or without TP53 changes. These are likely pathogenic, since ectopic expression of mutant KRAS <superscript>G12D</superscript> in the pleural mesothelium of conditional mice causes epithelioid MPM and cooperates with TP53 deletion to drive a more aggressive disease form with biphasic features and pleural effusions. Murine MPM cell lines derived from these tumors carry the initiating KRAS <superscript>G12D</superscript> lesions, secondary Bap1 alterations, and human MPM-like gene expression profiles. Moreover, they are transplantable and actionable by KRAS inhibition. Our results indicate that KRAS alterations alone or in accomplice with TP53 alterations likely play an important and underestimated role in a proportion of patients with MPM, which warrants further exploration.<br /> (© 2021 The Authors. Published under the terms of the CC BY 4.0 license.)

Details

Language :
English
ISSN :
1757-4684
Volume :
14
Issue :
2
Database :
MEDLINE
Journal :
EMBO molecular medicine
Publication Type :
Academic Journal
Accession number :
34898002
Full Text :
https://doi.org/10.15252/emmm.202013631